FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely neurooncology and may be used for treating benign cerebral tumours. That is ensured by using 4-methyl-3-[[4 (3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide and its N-oxide or pharmaceutically acceptable salt for preparing a pharmaceutical composition.
EFFECT: group of inventions allows treating benign cerebral tumours, particularly neurofibromatoses by means of inhibiting both signal pathways involving PDGFR and Kit receptors.
7 cl, 1 tbl, 2 ex
Authors
Dates
2012-05-20—Published
2006-12-05—Filed